Up to $2.4B in milestones In addition, Metsera shareholders will receive a non-transferable contingent value right (CVR) entitling them to potential additional payments of up to $22.50 per share cashadding up to $2.4 billion to the value of the dealtied to three specific clinical and regulatory milestones: $5 per share upon the start of Phase III clinical trials for Metseras MET-097i+MET-233i combination $7 per share upon FDA approval of Metseras monthly MET-097i monotherapy $10.50 per share upon FDA approval of Metseras monthly MET-097i+MET-233i combination The acquisition transaction is expected to close in the fourth quarter, subject to satisfying customary closing conditions, including receipt of required regulatory approvals and approval by Metseras shareholders
Some people prefer drinking lemon juice, while others like dabbing it on the skin for a skin lightening and glowing effect
Chronic pancreatitis: diagnosis, classification, and new genetic developments
Those with plasma B12 levels above 813 pg/mL (600 pmol/L) had a 1.74 to 4.72 times higher risk of being diagnosed with cancer within one year compared to those with levels in the normal range
One of its key roles is promoting protein synthesis, which is the building block for muscle
SOD catalyzes the conversion of superoxide (O 2 - ) into O 2 and H 2 O 2 557